Archives
Cisapride (R 51619): Redefining Cardiac Electrophysiology...
Cisapride (R 51619): Redefining Cardiac Electrophysiology and Predictive Toxicology in Translational Research
Cardiotoxicity remains a leading cause of late-stage drug attrition, posing both scientific and commercial risk to translational researchers. As the biomedical landscape pivots toward phenotypic screening and predictive toxicology, mechanistically robust tools like Cisapride (R 51619)—a nonselective 5-HT4 receptor agonist and potent hERG potassium channel inhibitor—are emerging as cornerstones for innovation in cardiac and gastrointestinal research. This article bridges mechanistic insight, experimental best practices, and strategic guidance, offering a roadmap for researchers seeking to elevate the rigor and translational relevance of their discovery programs.
Biological Rationale: Dual Mechanisms, Expansive Utility
Cisapride (R 51619) is chemically defined as 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide (MW 465.95). Its dual activity as both a nonselective 5-HT4 receptor agonist and a hERG potassium channel inhibitor underpins its unique value in translational research:
- 5-HT4 Receptor Agonism: By stimulating 5-HT4 receptor-mediated signaling pathways, Cisapride modulates gastrointestinal motility and neuronal transmission, providing a mechanistic basis for gastrointestinal motility studies and enteric pharmacology.
- hERG Channel Inhibition: As a potent inhibitor of the human ether-à-go-go-related gene (hERG) potassium channel, Cisapride enables precise interrogation of cardiac electrophysiology, arrhythmogenesis, and predictive cardiotoxicity—key considerations in cardiac arrhythmia research and drug safety assessment.
This dual mechanism is rarely matched by other small molecules, positioning Cisapride (often referenced as cisaprode, cisparide, or cispride in the literature) as a versatile tool for dissecting signaling complexity and off-target risk in preclinical models.
Experimental Validation: From Deep Learning to iPSC-Derived Cardiac Models
Modern cardiac electrophysiology research demands systems that mirror human physiology while supporting high-content, scalable interrogation. The integration of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with advanced analytics such as deep learning has redefined the landscape.
In a landmark study (Grafton et al., eLife 2021), researchers demonstrated that combining high-content image analysis, deep learning, and iPSC-CMs enables rapid, phenotypic detection of cardiotoxic liabilities across diverse compound libraries. Their approach:
- Screened 1,280 bioactive compounds—including ion channel blockers like Cisapride—using iPSC-CMs and automated imaging.
- Applied deep learning to generate single-parameter scores reflecting compound-induced cardiotoxicity, revealing molecular frameworks with hERG liability.
- Highlighted the predictive accuracy and scalability of this platform, supporting de-risking at early drug discovery stages and empowering target-agnostic, phenotypic screening.
As the study emphasizes: "By using this screening approach during target discovery and lead optimization, we can de-risk early-stage drug discovery." (Grafton et al., 2021). Cisapride (R 51619), with its well-characterized hERG inhibitory profile, is routinely employed as a positive control or reference compound in such workflows, allowing benchmarking of both assay sensitivity and compound-specific risk.
Our recent review, "Cisapride (R 51619): Integrating Deep Learning and iPSC Models", explores how this compound catalyzes new dimensions in predictive toxicology. This present article, however, escalates the discussion by embedding mechanistic rationale, translational imperatives, and workflow optimization into a cohesive, strategic framework for biomedical innovators.
Competitive Landscape: Why Cisapride (R 51619) Sets the Standard
While several small molecules can inhibit the hERG potassium channel or act as 5-HT4 receptor agonists, few combine these features with the purity, solubility spectrum, and robust quality control of APExBIO’s Cisapride (R 51619) (SKU B1198). Key differentiators include:
- Analytical Confidence: Each lot is supplied with comprehensive quality documentation (HPLC, NMR, MSDS) and verified at ≥99.70% purity.
- Versatile Solubility: Soluble at ≥23.3 mg/mL in DMSO and ≥3.47 mg/mL in ethanol, supporting diverse assay formats (although insoluble in water).
- Stability Assurance: Optimized for -20°C storage; short-term solution use minimizes degradation risk.
- Reproducibility: Validated in peer-reviewed protocols, enabling seamless integration into high-content screens and iPSC-derived cell assays (see related article).
APExBIO’s commitment to quality and traceability ensures your translational research is both reproducible and publication-ready—an essential consideration as regulatory and journal standards tighten for cell-based and phenotypic screening workflows.
Translational Relevance: De-Risking Drug Discovery and Advancing Precision Medicine
Harnessing Cisapride (R 51619) in your experimental pipeline offers distinct strategic advantages:
- Predictive Cardiotoxicity Modeling: As a canonical hERG channel inhibitor, Cisapride is invaluable for calibrating and validating phenotypic screens designed to flag arrhythmogenic risk. The Grafton et al. study underscores how iPSC-CMs and deep learning can uncover subtle, dose-dependent effects—enabling earlier, more accurate go/no-go decisions.
- 5-HT4 Receptor Pathway Interrogation: Nonselective agonism by Cisapride facilitates mechanistic mapping of serotonergic signaling, directly informing gastrointestinal motility studies and neurogastroenterology research.
- Workflow Optimization: High solubility in DMSO/ethanol and batch-to-batch consistency streamline integration into automated, high-throughput platforms, minimizing technical variability and supporting robust SAR (structure–activity relationship) analyses.
- Regulatory Alignment: Use of a gold-standard reference compound like Cisapride strengthens the translational alignment of your preclinical data, ensuring findings are defensible for IND-enabling studies and publication.
For clinical translation, these advances mean fewer surprises at the interface of preclinical and clinical development, smoother regulatory review, and accelerated timelines for first-in-human studies. As deep learning and iPSC technology become mainstream, the demand for validated controls like Cisapride (R 51619) will only intensify.
Visionary Outlook: Charting the Future of Phenotypic Screening and Mechanistic Discovery
The convergence of high-purity research compounds, physiologically relevant cell models, and AI-driven analytics is reshaping the boundaries of translational science. Cisapride (R 51619), by virtue of its well-studied dual mechanism, stands not just as a tool but as a benchmark for next-generation workflows:
- Multiplexed Assay Readouts: New protocols leverage Cisapride in multiplexed screens, simultaneously interrogating electrophysiology, cytotoxicity, and pathway activation—unlocking richer, more predictive datasets (see scenario-driven guidance).
- Personalized Models: Paired with patient-derived iPSC-CMs, Cisapride enables functional genomics studies that bridge genotype and phenotype, accelerating precision medicine initiatives.
- Open Science and Collaborative Benchmarks: As highlighted in Grafton et al., open sharing of high-content screening datasets and analytical pipelines amplifies the collective impact of well-characterized tool compounds like Cisapride.
Most product pages stop at technical data and basic use cases. This article, by contrast, synthesizes mechanistic logic, protocol optimization, and strategic foresight—empowering researchers not only to execute, but to innovate. As the landscape evolves, APExBIO’s Cisapride (R 51619) is poised to remain an anchor for both foundational studies and disruptive translational strategies.
Actionable Guidance: Best Practices for Translational Researchers
To fully harness the potential of Cisapride in cardiac electrophysiology research and predictive toxicology, consider the following best practices:
- Optimize Concentrations: Exploit the compound’s high solubility in DMSO or ethanol for precise titration; avoid long-term storage of solutions to maintain potency.
- Validate Assay Windows: Use Cisapride as a reference in iPSC-derived cardiomyocyte models to define assay sensitivity and dynamic range, as demonstrated in deep learning-enabled screens (Grafton et al.).
- Ensure Reproducibility: Source high-purity, quality-controlled material from trusted vendors such as APExBIO to guarantee data integrity across experiments.
- Integrate with High-Content Analytics: Leverage automated imaging and machine learning to extract nuanced, phenotypic insights from Cisapride-treated cells—de-risking lead selection and SAR studies.
- Consult Scenario-Driven Protocols: For practical troubleshooting and nuanced data interpretation, refer to scenario-driven best practices (see detailed guidance).
Conclusion: Catalyzing Innovation Beyond Conventional Product Pages
Translational research is at a crossroads—demanding models and reagents that are not only robust in isolation but synergize within complex, scalable workflows. Cisapride (R 51619), as supplied by APExBIO, occupies a rarefied position at the intersection of mechanistic insight and translational utility. By integrating deep learning, iPSC-derived models, and validated tool compounds, today’s researchers can de-risk drug discovery, accelerate therapeutic innovation, and ultimately improve patient outcomes.
This article transcends the limits of standard product pages by embedding strategic, mechanistic, and workflow-centric insights—empowering the next wave of translational breakthroughs. For advanced cardiac electrophysiology and predictive toxicology, APExBIO’s Cisapride (R 51619) is more than a reagent; it’s a catalyst for discovery.